Catharina Müller-Thomas

Catharina Müller-Thomas

Auto-generated profile, based on publicly available information

Catharina Müller-Thomas

Klinik für Hämatologie, Onkologie und Stammzelltransplantation, München Klinik Schwabing, München, Deutschland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2019 in Experimental Hematology & Oncology
Verified
Journal Article
Open access
PDF file
SJStefanie Jilg
Stefanie Jilg
RHRichard T. Hauch
Richard T. Hauch
JKJohanna Kauschinger
Johanna Kauschinger
LBLars Buschhorn
Lars Buschhorn
TOTimo O. Odinius
Timo O. Odinius
PJPhilipp J. Jost
Philipp J. Jost
Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effective salvage therapy, for which only a limited number of patients are eligible due to age and comorbidity. Combination therapy of venetoclax and azacitidine (5-AZA) seems to be a promising approach in myeloid malignancies, but data from patients with HMA failure are lacking. Furthermore, a considerable concern of combination regimens in elderly AML and MDS patients is the toxicity on the remaining healthy hematopoiesis. Here, we report in vitro data showing the impact of venetoclax and 5-AZA, alone or in combination, in a larger cohort of MDS/sAML patients (n = 21), even after HMA failure (n = 13). We especially focused on the effects on healthy hematopoiesis and the impact on colony forming capacity as a parameter for long-term effects. To the best of our knowledge, we show for the first time that venetoclax in combination with capped dose of 5-AZA targets cell malignancies, while sparing healthy hematopoiesis.

17 April 2019 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
CGChristina Ganster
Christina Ganster
CMCatharina Müller‐Thomas
Catharina Müller‐Thomas
CHClaudia Haferlach
Claudia Haferlach
CSCorinna Strupp
Corinna Strupp
KOKiyoyuki Ogata
Kiyoyuki Ogata
DHDetlef Haase
Detlef Haase

16 November 2012 in Blood
Verified
Journal Article
Open access
FBFriederike Braulke
Friederike Braulke
JSJulie Schanz
Julie Schanz
KGKatharina Goetze
Katharina Goetze
CMCatharina Müller-Thomas
Catharina Müller-Thomas
UPUwe Platzbecker
Uwe Platzbecker
DHDetlef Haase
Detlef Haase
Abstract 3816

9 April 2019 in Acta Haematologica
Verified
Journal Article
Closed access
PDF file
CMCatharina Müller-Thomas
Catharina Müller-Thomas
HTHeinz Tüchler
Heinz Tüchler
MRMartina Rudelius
Martina Rudelius
HSHeike Schneider
Heike Schneider
SPSabrina Pfefferkorn
Sabrina Pfefferkorn
KGKatharina S. Götze
Katharina S. Götze
Background/Aims: There is growing evidence supporting the role of innate immune deregulation and inflammation in the pathogenesis of myelodysplastic syndromes (MDS). Vitamin D (VD) is known to be involved in various immune and epigenetic processes. This analysis aimed to evaluate serum VD levels in patients with MDS and to analyze associations between serum VD levels and disease characteristics. Methods: Serum levels of 25-hydroxyvitamin D3 (25(OH)-D3), the major form of VD in human serum, were measured by chemiluminescence immunoassay in 62 unselected patients with MDS. Associations between serum 25(OH)-D3 levels and disease characteristics were analyzed using Kendall’s tau and two-sided p values. Results: The median serum 25(OH)-D3 level was markedly reduced (17.5 ng/mL). Patients with lower-risk disease features had lower serum 25(OH)-D3 levels than patients with higher-risk disease features with regard to medullary blast counts (16 vs. 31 ng/mL, p < 0.001), the revised international prognostic scoring system (13 vs. 30.5 ng/mL, p = 0.001), and blood counts. Conclusions: We show that patients with lower-risk disease characteristics exhibit lower serum VD levels than patients with higher-risk disease characteristics. Whether these findings might reflect innate immune deregulation has to be investigated in further studies.

31 August 2021 in Die Innere Medizin
Verified
Journal Article
Closed access
PDF file
CMC. Müller-Thomas
C. Müller-Thomas